The Focal Segmental Glomerulosclerosis Treatment market faces challenges due to the complexity of the disease and variability in treatment response. The absence of a universally effective therapy creates an ongoing need for new clinical solutions. The focal segmental glomerulosclerosis (FSGS) treatment market was valued at US$ 2.39 billion in 2025 and is expected to reach US$ 3.98 billion by...